Skip to main content

Microbial Colonization

1
Pipeline Programs
7
Companies
5
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

6 companies ranked by most advanced pipeline stage

Human BioSciences
Human BioSciencesWV - Martinsburg
1 program
1
AmpicillinPhase 41 trial
Active Trials
NCT03997266Completed359Est. Jan 2026
Becton Dickinson
Becton DickinsonFRANKLIN LAKES, NJ
1 program
CHG/IPAN/A1 trial
Active Trials
NCT04035161Completed1,935Est. Dec 2019
Verona Pharma
Verona PharmaUK - London
1 program
Microbiome evaluationN/A1 trial
Active Trials
NCT04274972Unknown20Est. Dec 2024
Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
1 program
OneBiome microbiome profiling serviceN/A1 trial
Active Trials
NCT04991818Completed90Est. Apr 2022
Paratek Pharmaceuticals
1 program
Omadacycline InjectionPHASE_41 trial
Active Trials
NCT05515562Completed8Est. Jul 2023
AB Science
AB ScienceFrance - Paris
1 program
probioticsPhase N/A

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Paratek PharmaceuticalsOmadacycline Injection
Human BioSciencesAmpicillin
Allergy TherapeuticsOneBiome microbiome profiling service
Verona PharmaMicrobiome evaluation
Becton DickinsonCHG/IPA

Clinical Trials (5)

Total enrollment: 2,412 patients across 5 trials

Effects of Intravenous (IV) Omadacycline on Gut Microbiome

Start: Mar 2023Est. completion: Jul 20238 patients
Phase 4Completed

NICU Antibiotics and Outcomes Trial

Start: Aug 2020Est. completion: Jan 2026359 patients
Phase 4Completed
NCT04991818Allergy TherapeuticsOneBiome microbiome profiling service

MSC - OneBiome UX Pilot Study

Start: Sep 2021Est. completion: Apr 202290 patients
N/ACompleted
NCT04274972Verona PharmaMicrobiome evaluation

The Microbiome of Pancreatic Cancer: "PANDEMIC" Study

Start: Feb 2020Est. completion: Dec 202420 patients
N/AUnknown

Evaluation of the Antimicrobial Effectiveness of CHG/IPA

Start: Apr 2019Est. completion: Dec 20191,935 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

7 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.